Multifaceted transforming growth factor-beta (TGFβ) signalling in glioblastoma.

Autor: Birch JL; CRUK Beatson Institute, Glasgow, UK., Coull BJ; Division of Cellular and Molecular Medicine, School of Medicine, University of Dundee, Dundee, UK., Spender LC; Division of Molecular and Clinical Medicine, School of Medicine, University of Dundee, Dundee, UK., Watt C; Division of Cellular and Molecular Medicine, School of Medicine, University of Dundee, Dundee, UK., Willison A; Division of Cellular and Molecular Medicine, School of Medicine, University of Dundee, Dundee, UK., Syed N; The John Fulcher Molecular Neuro-Oncology Laboratory, Division of Brain Sciences, Imperial College London, London, UK., Chalmers AJ; Institute of Cancer Sciences, University of Glasgow, Glasgow, UK., Hossain-Ibrahim MK; Division of Cellular and Molecular Medicine, School of Medicine, University of Dundee, Dundee, UK; Department of Neurosurgery, Ninewells Hospital and Medical School, NHS Tayside, Dundee, UK., Inman GJ; CRUK Beatson Institute, Glasgow, UK; Division of Cellular and Molecular Medicine, School of Medicine, University of Dundee, Dundee, UK; Institute of Cancer Sciences, University of Glasgow, Glasgow, UK. Electronic address: gareth.inman@glasgow.ac.uk.
Jazyk: angličtina
Zdroj: Cellular signalling [Cell Signal] 2020 Aug; Vol. 72, pp. 109638. Date of Electronic Publication: 2020 Apr 19.
DOI: 10.1016/j.cellsig.2020.109638
Abstrakt: Glioblastoma (GBM) is an aggressive and devastating primary brain cancer which responds very poorly to treatment. The average survival time of patients is only 14-15 months from diagnosis so there is a clear and unmet need for the development of novel targeted therapies to improve patient outcomes. The multifunctional cytokine TGFβ plays fundamental roles in development, adult tissue homeostasis, tissue wound repair and immune responses. Dysfunction of TGFβ signalling has been implicated in both the development and progression of many tumour types including GBM, thereby potentially providing an actionable target for its treatment. This review will examine TGFβ signalling mechanisms and their role in the development and progression of GBM. The targeting of TGFβ signalling using a variety of approaches including the TGFβ binding protein Decorin will be highlighted as attractive therapeutic strategies.
(Copyright © 2020 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: